Kun-chieh Chen

No.110, Sec. 1, Jianguo N. Road, 402
Taitung, TNQ, Taiwan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 70 publications

Stage shifts in national lung adenocarcinoma and the impact of opportunistic self-initiated LDCT screening in Taiwan: a nationwide population-based cohort study.

Stage shifts in national lung adenocarcinoma and the impact of opportunistic self-initiated LDCT screening in Taiwan: a nationwide population-based cohort study.

Journal: The Lancet regional health. Western Pacific

Published: January 29, 2026

Combination Therapy With MET Tyrosine Kinase Inhibitor and EGFR Tyrosine Kinase Inhibitor in Patients With MET-Overexpressed EGFR-Mutant Lung Adenocarcinoma.

Combination Therapy With MET Tyrosine Kinase Inhibitor and EGFR Tyrosine Kinase Inhibitor in Patients With MET-Overexpressed EGFR-Mutant Lung Adenocarcinoma.

Journal: JTO clinical and research reports

Published: December 29, 2024

Osimertinib as Second- and ≥Third-Line Treatment in Advanced and Recurrence EGFR-Mutant NSCLC Patients Harboring Acquired T790M Mutation.

Osimertinib as Second- and ≥Third-Line Treatment in Advanced and Recurrence EGFR-Mutant NSCLC Patients Harboring Acquired T790M Mutation.

Journal: Cancers

Published: November 07, 2024

Taiwan Nationwide Study of First-Line ALK-TKI Therapy in ALK-Positive Lung Adenocarcinoma.

Taiwan Nationwide Study of First-Line ALK-TKI Therapy in ALK-Positive Lung Adenocarcinoma.

Journal: Targeted oncology

Published: September 18, 2024

Polygenic Risk Score and Lung Adenocarcinoma Risk Among Never-Smokers by EGFR Mutation Status: A Brief Report.

Polygenic Risk Score and Lung Adenocarcinoma Risk Among Never-Smokers by EGFR Mutation Status: A Brief Report.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: September 06, 2024

Integrative analysis of lung adenocarcinoma across diverse ethnicities and exposures.

Integrative analysis of lung adenocarcinoma across diverse ethnicities and exposures.

Journal: Cancer cell

Published: July 19, 2024

Real-world clinical efficacy of bevacizumab biosimilar in patients with advanced non-small-cell lung cancer.

Real-world clinical efficacy of bevacizumab biosimilar in patients with advanced non-small-cell lung cancer.

Journal: Therapeutic advances in medical oncology

Published: May 23, 2024

Primary tumor consolidative therapy improves the outcomes of patients with advanced EGFR-mutant lung adenocarcinoma treated with first-line osimertinib.

Primary tumor consolidative therapy improves the outcomes of patients with advanced EGFR-mutant lung adenocarcinoma treated with first-line osimertinib.

Journal: Therapeutic advances in medical oncology

Published: June 22, 2023

Low-dose CT screening among never-smokers with or without a family history of lung cancer in Taiwan: a prospective cohort study.

Low-dose CT screening among never-smokers with or without a family history of lung cancer in Taiwan: a prospective cohort study.

Journal: The Lancet. Respiratory medicine

Published: May 09, 2023

Artificial Intelligence Assisted Computational Tomographic Detection of Lung Nodules for Prognostic Cancer Examination: A Large-Scale Clinical Trial.

Artificial Intelligence Assisted Computational Tomographic Detection of Lung Nodules for Prognostic Cancer Examination: A Large-Scale Clinical Trial.

Journal: Biomedicines

Published: November 19, 2022

Adjuvant chemotherapy compared with observation in patients with T2aN0 stage IB lung adenocarcinoma.

Adjuvant chemotherapy compared with observation in patients with T2aN0 stage IB lung adenocarcinoma.

Journal: Frontiers in oncology

Published: November 12, 2022

Correction to: The Difference in Clinical Outcomes Between Osimertinib and Afatinib for First-Line Treatment in Patients with Advanced and Recurrent EGFR-Mutant Non-Small Cell Lung Cancer in Taiwan.

Correction to: The Difference in Clinical Outcomes Between Osimertinib and Afatinib for First-Line Treatment in Patients with Advanced and Recurrent EGFR-Mutant Non-Small Cell Lung Cancer in Taiwan.

Journal: Targeted oncology

Published: November 05, 2022

Showing 1-12 of 70

Last Updated: 09/26/2026